Overland Pharmaceuticals, backed by Hillhouse Capital, is building a fully integrated biopharma company with a mission to bring innovative medicines to underserved patients in Asia and around the world.

By leveraging our resources, global network, and local expertise across the biopharma ecosystem in Asia, Overland is establishing a portfolio of differentiated therapeutic candidates in a few carefully selected therapeutic areas.

Through formative R&D partnerships, Overland will move forward the development and commercialization of the most promising advances in medicine.


Innovation for patients

Through strategically engineered alliances, Overland focuses on innovative therapeutic programs and cutting-edge technology platforms to deliver maximum value to all stakeholders with the ultimate goal of serving patients around the world.

Flexibility for partners

Overland’s flexible business approach and ability to architect differing partnership models (e.g. joint-venture, licensing, and equity investment deal structures), coupled with deep local expertise and a strong track record of achieving drug approvals in greater China, allows both Overland and its partners to benefit from each other’s respective strengths.

Efficiency for programs

Therapeutic candidate programs across our portfolio are developed by our dedicated clinical and regulatory teams and other shared functional resources to achieve peak operational and capital efficiency.


Deep integrity

We are committed to putting patients first and aim at fostering a culture of strong ethics and a high standard for quality.

Entrepreneurial spirit

We are launching a robust research and development engine of differentiated, novel therapeutics – all with the spirit and ambition of a nimble biotech.

Global collaboration

Overland collaborates with innovative partners to jointly develop and strategically commercialize therapeutic programs for entry into Asia and expansion around the globe.

Agility & efficiency

We accelerate the development of and access to promising new medicines for patients by sourcing the brightest talents and centralizing key operations.


Ed Zhang, MBA

Chief Executive Officer

Roger Luo, PhD

Chief Development Officer, Head of Clinical and Preclinical Development

Jie Li

Chief Regulatory Officer

Xun Liu, PhD

Chief Technology Officer

Jie Chen, MD, PhD

Head of Biometrics

Warren Li, PhD

Vice President,
Head of Translational Medicine

Julia Zhu, MD, PhD

Vice President,
Head of Drug Safety and Pharmacovigilance

Helen YANG

Vice President,
Head of Clinical Operations and Project Management

Julie Zhang, MBA

Vice President, Oncology Regulatory Affairs Lead and Government Affairs Lead

Kenneth Gao, MBA

Vice President,
Alliance Management and Corporate Development

Eric Hu, PhD

Vice President,
Business Development

Serena Wang, MBA

Vice President, Head of Finance, IT and Procurement

Weijie Lan, PhD

Vice President,
Head of Cell Therapy Platform Research

John Maraganore, PhD

Peter Ho, MD, PHD


Chief Executive Officer,
Overland ADCT BioPharma

Shuyuan Yao, PhD

Chief Executive Officer,
Allogene Overland Biopharm